Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

First Successful Clinical Trial of VU319 Brings Alzheimer's Treatment One Step Closer ... neuroinflammation in Alzheimer's disease. The study also integrates drug databases ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

Diet, exercise, brain games, even using your non-dominant hand can help prevent the onset of Alzheimer's disease.

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...

There’s intriguing news today about a technology that could improve treatment in people with Alzheimer’s. It uses sound waves ...

Posdinemab works by targeting and neutralizing Alzheimer disease-specific phosphorylated tau, preventing its spread to other neurons.